| 2025-11-13 |
财报披露：
美东时间 2025-11-13 盘前发布财报
|
| 2025-11-12 |
详情>>
股本变动：
变动后总股本1118.44万股
|
| 2025-11-12 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.21美元,归母净利润-1304.52万美元,同比去年增长12.48%
|
| 2025-09-16 |
复牌提示：
2025-09-16 08:25:00 停牌，复牌日期 2025-09-16 08:45:00
|
| 2025-08-13 |
详情>>
业绩披露：
2025年中报每股收益-0.82美元,归母净利润-886.78万美元,同比去年增长14.74%
|
| 2025-08-08 |
股东大会：
将于2025-09-19召开股东大会
会议内容 ▼▲
- 1.To elect six directors to serve as members of the Board of Directors of the Company (which we refer to as our “Board”) until the next annual meeting of stockholders and until their successors are duly elected and qualified. The director nominees named in the Proxy Statement for election to our Board are: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Lee T. Schalop, and David S. Silberstein;
2.To approve the one-time repricing of certain stock options granted under the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended (the “Equity Incentive Plan”);
3.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025;
4.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposals.
|
| 2025-05-15 |
详情>>
业绩披露：
2025年一季报每股收益-0.42美元,归母净利润-453.68万美元,同比去年增长16.62%
|
| 2025-03-27 |
详情>>
业绩披露：
2024年年报每股收益-1.93美元,归母净利润-2078.12万美元,同比去年增长-30.2%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.39美元,归母净利润-1490.6万美元,同比去年增长-26.58%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.97美元,归母净利润-1040.03万美元,同比去年增长-20.74%
|
| 2024-07-24 |
详情>>
内部人交易：
KEYSER D JEFFREY股份增加3832.00股
|
| 2024-05-09 |
详情>>
业绩披露：
2024年一季报每股收益-0.51美元,归母净利润-544.08万美元,同比去年增长-40.67%
|
| 2024-04-29 |
股东大会：
将于2024-06-13召开股东大会
会议内容 ▼▲
- 1.To elect five directors to serve as members of the Board of Directors of the Company (which we refer to as our “Board”) until the next annual meeting of stockholders and until their successors are duly elected and qualified. The director nominees named in the Proxy Statement for election to our Board are: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, and David S. Silberstein;
2.To approve an amendment to the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended (the “Equity Incentive Plan”) to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 125,000 shares;
3.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024;
4.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposals.
|
| 2024-03-18 |
详情>>
业绩披露：
2023年年报每股收益-1.47美元,归母净利润-1596.15万美元,同比去年增长-11.93%
|
| 2023-11-08 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.08美元,归母净利润-1177.56万美元,同比去年增长-8.24%
|
| 2023-04-28 |
股东大会：
将于2023-06-16召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to serve as members of the Board of Directors of the Company (which we refer to as our “Board”) until the next annual meeting of stockholders and until their successors are duly elected and qualified. The director nominees named in the Proxy Statement for election to our Board are: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, and David S. Silberstein;
2.To approve an amendment to the Second Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan (the “Equity Incentive Plan”) to increase the number of shares of the Company’s common stock available for issuance under the Equity Incentive Plan by an additional 250,000 shares;
3.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023;
4.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposals.
|
| 2022-04-27 |
股东大会：
将于2022-06-08召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to serve as members of the Board of Directors of the Company (which we refer to as our “Board”) until the next annual meeting of stockholders and until their successors are duly elected and qualified. The director nominees named in the Proxy Statement for election to our Board are: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Maria Maccecchini, Franklyn Prendergast, and David S. Silberstein;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2022;
3.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposals.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-09 |
股东大会：
将于2021-05-19召开股东大会
会议内容 ▼▲
- 1.To elect six (6) directors to serve as members of the Board of Directors of the Company (which we refer to as our “Board”) until the next annual meeting of stockholders and until their successors are duly elected and qualified. The director nominees named in the Proxy Statement for election to our Board are: Donald Jeff Keyser, Panna Sharma, Vijay Chandru, Leslie W. Kreis, Jr., Franklyn Prendergast, and David S. Silberstein;
2.To ratify the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2021;
3.To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the foregoing proposals;
4.To transact such other business as may properly come before the Annual Meeting or at any continuation, postponement or adjournment thereof.
|